Primary systemic sclerosis heart involvement (pSHI) is an important disease manifestation
that accounts for a significant proportion of systemic sclerosis (SSc)-associated mortality. A …

Pulmonary arterial hypertension (PAH) is a dreaded complication of systemic sclerosis (SSc)
that occurs in∼ 10% of patients. Most individuals present with severe symptoms, significant …

Objective Pulmonary arterial hypertension (PAH) affects up to 15% of patients with
connective tissue diseases (CTDs). Previous recommendations developed as part of larger …

We sought to investigate the characteristics, survival and risk factors for mortality in Chinese
patients with connective tissue disease (CTD)-associated pulmonary arterial hypertension …

BACKGROUND: Patients with pulmonary arterial hypertension (PAH) associated with
systemic sclerosis (SSc-APAH) experience higher mortality rates than patients with …

Objectives. Pulmonary arterial hypertension (PAH) is associated with rapid deterioration and
poor prognosis in SLE, especially during pregnancy. The prevalence of PAH in SLE in non …

Rationale: To date, it remains unclear whether recent changes in the management of
patients with systemic sclerosis–associated pulmonary hypertension (SSc-PH) have …

Pulmonary arterial hypertension (PAH), corresponding to group 1 of pulmonary
hypertension classification, is a rare disease with a major prognostic impact on morbidity …

Pulmonary hypertension (PH) is a clinical condition characterized by increased pulmonary
arterial pressure arising from a heterogeneous range of diseases that has a deteriorating …

Lung illness encountered in patients with rheumatic diseases bears clinical significance in
terms of increased morbidity and mortality as well as potential challenges placed on patient …